Profile data is unavailable for this security.
About the company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
- Revenue in CAD (TTM)0.00
- Net income in CAD-8.22m
- Incorporated2006
- Employees11.00
- LocationBriacell Therapeutics CorpSuite 300 - Bellevue Centre235 -15th StreetWEST VANCOUVER V7T 2X1CanadaCAN
- Phone+1 (604) 921-1810
- Fax+1 (604) 921-1898
- Websitehttps://briacell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thiogenesis Therapeutics Corp | 0.00 | -4.49m | 30.62m | -- | -- | 6.41 | -- | -- | -0.1092 | -0.1092 | 0.00 | 0.1045 | 0.00 | -- | -- | -- | -91.94 | -- | -98.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Avicanna Inc | 24.87m | -7.44m | 35.98m | 38.00 | -- | 996.92 | -- | 1.45 | -0.0804 | -0.0804 | 0.2714 | 0.0003 | 1.20 | 2.95 | 9.32 | 654,600.00 | -35.85 | -67.17 | -267.70 | -167.73 | 48.66 | 46.36 | -29.90 | -368.82 | 0.3316 | -8.88 | 0.1645 | -- | 314.82 | 169.57 | 40.67 | -- | -32.29 | -- |
| Nurexone Biologic Inc | 0.00 | -5.68m | 38.02m | 8.00 | -- | 10.65 | -- | -- | -0.1093 | -0.1093 | 0.00 | 0.0526 | 0.00 | -- | -- | -- | -183.97 | -213.78 | -235.34 | -596.97 | -- | -- | -- | -- | -- | -187.27 | 0.0096 | -- | -- | -- | 55.45 | -- | -- | -- |
| Briacell Therapeutics Corp | 0.00 | -8.22m | 46.08m | 11.00 | -- | -- | -- | -- | -0.5365 | -0.5365 | 0.00 | -0.5117 | 0.00 | -- | -- | 0.00 | -33.97 | -59.37 | -43.50 | -63.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.35 | -- | -- | -- |
| Microbix Biosystems Inc | 23.36m | 5.08m | 47.02m | 69.00 | 9.34 | 1.68 | 7.13 | 2.01 | 0.0369 | 0.0369 | 0.1695 | 0.205 | 0.6488 | 1.63 | 6.35 | -- | 14.10 | -0.9729 | 16.10 | -1.17 | 57.21 | 52.30 | 21.73 | -1.55 | 4.89 | 5.93 | 0.1849 | -- | -13.43 | 5.71 | -102.21 | -- | -3.56 | -- |
| KDA Group Inc | 204.14k | -876.18k | 51.13m | -- | -- | 3.53 | -- | 250.46 | -0.0027 | 0.0783 | 0.0013 | 0.0821 | 0.008 | -- | 0.0835 | -- | -4.63 | -17.96 | -8.47 | -44.69 | 33.32 | 26.76 | -574.97 | -28.00 | -- | -7.08 | 0.0606 | -- | -22.20 | -62.03 | 106.88 | -- | 31.67 | -- |
| Helix Biopharma Corp. | 0.00 | -6.14m | 53.19m | 9.00 | -- | -- | -- | -- | -0.1478 | -0.1478 | 0.00 | -0.0079 | 0.00 | -- | -- | 0.00 | -449.73 | -261.49 | -2,225.00 | -- | -- | -- | -- | -- | -- | -265.96 | -- | -- | -- | -- | 4.16 | -- | -28.36 | -- |
| MustGrow Biologics Corp | 4.71m | -423.96k | 61.86m | 0.00 | -- | 17.09 | -- | 13.13 | -0.0078 | -0.0078 | 0.0927 | 0.0726 | 0.9337 | -- | 32.60 | -- | -8.40 | -50.41 | -11.41 | -59.28 | -- | -- | -9.00 | -298.73 | 4.84 | -- | 0.1215 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| ZYUS Life Sciences Corp | 428.00k | -36.83m | 63.50m | 2.00 | -- | 3.88 | -- | 148.35 | -0.5247 | -0.5247 | 0.0061 | 0.2192 | 0.0074 | 0.075 | 0.5757 | -- | -63.34 | -57.88 | -88.37 | -71.19 | 46.50 | -16.16 | -8,604.67 | -10,367.37 | 0.1593 | -35.94 | 0.3955 | -- | 17.79 | 213.99 | -72.73 | -- | -- | -- |
| Satellos Bioscience Inc | 0.00 | -23.05m | 67.06m | 12.00 | -- | 2.28 | -- | -- | -0.2044 | -0.2044 | 0.00 | 0.2585 | 0.00 | -- | -- | 0.00 | -53.45 | -107.22 | -57.45 | -136.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.33 | -- | 459.46 | -- |
